直接口服抗凝药与维生素K拮抗剂治疗脑静脉血栓形成的比较:系统综述与荟萃分析
该系统综述与荟萃分析纳入14项研究(8项随机临床试验和6项观察性研究),共3698例脑静脉血栓形成患者,比较直接口服抗凝药与维生素K拮抗剂的疗效与安全性。结果显示两组在复发性静脉血栓栓塞、大出血、临床相关非大出血、良好功能结局和死亡率方面均相似。作者认为直接口服抗凝药是合理的替代选择。
要点
- 直接口服抗凝药与维生素K拮抗剂在复发性静脉血栓栓塞和大出血风险上相似。
- 两组在临床相关非大出血、良好功能结局(改良Rankin量表评分0–2分)和死亡率方面也相似。
- 直接凝血酶抑制剂与Xa因子抑制剂比较,各结局无显著差异。
核心结论
- 直接口服抗凝药在脑静脉血栓形成治疗中表现出与维生素K拮抗剂相当的有效性和安全性,这些发现支持将直接口服抗凝药作为合理的替代选择。
研究设计与样本
- 系统综述与荟萃分析,纳入2007年1月至2025年7月发表的随机对照试验和观察性研究,共14项研究(8项随机临床试验和6项观察性研究),3698例患者,其中1669例(45.1%)接受直接口服抗凝药,2029例(54.9%)接受维生素K拮抗剂。
主要发现
- 复发性静脉血栓栓塞发生率直接口服抗凝药组为10.24%,维生素K拮抗剂组为10.99%。
- 大出血发生率直接口服抗凝药组为4.26%,维生素K拮抗剂组为6.18%。
- 临床相关非大出血发生率直接口服抗凝药组为2.63%,维生素K拮抗剂组为1.66%。
- 良好功能结局发生率直接口服抗凝药组为95.09%,维生素K拮抗剂组为89.25%;死亡率直接口服抗凝药组为3.37%,维生素K拮抗剂组为3.30%。
- 随机临床试验中复发性静脉血栓栓塞的风险比(RR)为1.06(95%CI 0.35–3.24),总体汇总分析RR为0.92(95%CI 0.55–1.53);大出血在随机临床试验中RR为0.73(95%CI 0.24–2.22),总体分析RR为0.74(95%CI 0.44–1.25;P=0.26);临床相关非大出血在随机临床试验中RR为1.06(95%CI 0.25–4.48),总体分析RR为1.22(95%CI 0.38–3.86);良好功能结局在随机临床试验中RR为1.00(95%CI 0.84–1.19),总体分析RR为1.02(95%CI 0.93–1.11);死亡率在随机临床试验中RR为1.15(95%CI 0.28–4.68),总体汇总分析结果相似。
关键数值与推荐
- 复发性静脉血栓栓塞:直接口服抗凝药组10.24% vs 维生素K拮抗剂组10.99%;随机临床试验RR 1.06(95%CI 0.35–3.24),总体RR 0.92(95%CI 0.55–1.53)。
- 大出血:直接口服抗凝药组4.26% vs 维生素K拮抗剂组6.18%;随机临床试验RR 0.73(95%CI 0.24–2.22),总体RR 0.74(95%CI 0.44–1.25;P=0.26)。
- 临床相关非大出血:直接口服抗凝药组2.63% vs 维生素K拮抗剂组1.66%;随机临床试验RR 1.06(95%CI 0.25–4.48),总体RR 1.22(95%CI 0.38–3.86)。
- 良好功能结局(改良Rankin量表评分0–2分):直接口服抗凝药组95.09% vs 维生素K拮抗剂组89.25%;随机临床试验RR 1.00(95%CI 0.84–1.19),总体RR 1.02(95%CI 0.93–1.11)。
- 死亡率:直接口服抗凝药组3.37% vs 维生素K拮抗剂组3.30%;随机临床试验RR 1.15(95%CI 0.28–4.68),总体汇总分析结果相似。
临床怎么用
- 作者认为,这些发现支持将直接口服抗凝药作为脑静脉血栓形成治疗的合理替代选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke, Ahead of Print. BACKGROUND:Cerebral venous thrombosis is an uncommon cause of stroke that primarily affects young adults. Several clinical trials and observational studies have compared vitamin K antagonists (VKAs) with direct oral anticoagulants (DOACs) for treating cerebral venous thrombosis, but the small sample sizes limit the ability to draw firm conclusions.METHODS:We performed a systematic review and meta-analysis of randomized controlled trials and observational studies comparing DOACs with VKAs for the treatment of cerebral venous thrombosis. Studies published between January 2007 and July 2025 were included. Prespecified subgroup analyses were conducted by study design, DOAC class (anti–factor Xa inhibitors versus direct thrombin inhibitors), and VKA. Risk of bias was assessed using the Cochrane Risk-of-Bias Tool 2 for randomized trials and the Risk of Bias in Nonrandomized Studies of Interventions for observational studies. Pooled risk ratios (RRs) with 95% CIs were calculated using random-effects models.RESULTS:Fourteen studies (8 randomized clinical trials [RCTs] and 6 observational studies) were included. Among 3698 patients, 1669 (45.1%) received DOACs and 2029 (54.9%) received VKAs. Rates of recurrent venous thromboembolism (10.24% versus 10.99%), major bleeding (4.26% versus 6.18%), clinically relevant nonmajor bleeding (2.63% versus 1.66%), good functional outcomes (95.09% versus 89.25%), and mortality (3.37% versus 3.30%) were similar in DOACs and VKAs. Recurrent venous thromboembolism was similar between DOACs and VKAs in RCTs (RR, 1.06 [95% CI, 0.35–3.24]) and in the overall pooled analysis of all studies (RR, 0.92 [95% CI, 0.55–1.53]). Major bleeding did not differ between DOACs and VKAs in RCTs (RR, 0.73 [95% CI, 0.24–2.22]) or in the overall analysis (RR, 0.74 [95% CI, 0.44–1.25];P=0.26). Clinically relevant nonmajor bleeding was also comparable in RCTs (RR, 1.06 [95% CI, 0.25–4.48]) and overall (RR, 1.22 [95% CI, 0.38–3.86]). Good functional outcomes (modified Rankin Scale score of 0–2) were similar between DOACs and VKAs in RCTs (RR, 1.00 [95% CI, 0.84–1.19]) and in the combined analysis of all studies (RR, 1.02 [95% CI, 0.93–1.11]). Mortality was similar between DOACs and VKAs in RCTs (RR, 1.15 [95% CI, 0.28–4.68]) and in the pooled analysis. When direct thrombin inhibitors were compared with factor Xa inhibitors, there were no significant differences in outcomes.CONCLUSIONS:DOACs demonstrated comparable efficacy and safety to VKAs in the treatment of cerebral venous thrombosis. These findings support the use of DOACs as a reasonable alternative.
引用
- Stroke:Comparison of DOAC Versus VKA for Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。